BlackBerry Limited vs Summit Therapeutics Inc — how do they compare? BlackBerry Limited trades at $9.13 (market cap $5.18B), while Summit Therapeutics Inc trades at $15.21 (market cap $11.87B). The key difference: Summit Therapeutics Inc is far larger — about 2.3× BlackBerry Limited's market cap, and BlackBerry Limited is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| BB | SMMT | |
|---|---|---|
Market Cap | $5.18B | $11.87B |
Sector | Technology | Health |
52-Week High | $12.81 | $26.98 |
52-Week Low | $3.15 | $12.55 |
Enterprise Value | $5.05B | $11.20B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $13.96, up 3.1% today, but faces bearish technical signals with negative ROE of -192.5% and net income of -$1.08B for 2025. The company's key catalyst is the FDA review of ivonescimab with a November 2026 decision, supported by expanded clinical trials in bladder and kidney cancer. Cash flow remains dependent on financing activities, with operating cash flow negative at -$323M in 2025.
Investment outlook hinges on ivonescimab's FDA approval, with analyst consensus target at $27.90 offering significant upside. However, high execution risk, ongoing losses, and fiduciary investigations present substantial downside. The stock represents a high-risk biotech speculation with binary outcomes based on regulatory success.
Trailing returns across standard periods
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →